Skip to main content

Treatment Clinical Trials for Acute Lymphoblastic Leukemia (ALL)

Review the acute lymphoblastic leukemia (all) treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 165

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients with High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Status: Active
Location: 198 locations
A Study to Compare Blinatumomab Alone to Blinatumomab with Nivolumab in Patients Diagnosed with First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Status: Active
Location: 196 locations
Inotuzumab Ozogamicin in Treating Younger Patients with B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Active
Location: 136 locations
Testing the Use of Steroids and Tyrosine Kinase Inhibitors with Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
Status: Active
Location: 196 locations
Testing the use of Daratumumab-Hyaluronidase in Persistent or Recurrent T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) following Treatment with Chemotherapy
Status: Active
Location: 120 locations
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment with Blinatumomab for Children, Adolescents, and Young Adults with Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Status: Active
Location: 101 locations
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants with Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Status: Active
Location: 88 locations
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
Status: Active
Location: 18 locations
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: 15 locations
A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation
Status: Active
Location: 17 locations
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
Status: Active
Location: 11 locations
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Status: Active
Location: 11 locations
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
Status: Active
Location: 11 locations
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Status: Active
Location: 10 locations
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Status: Active
Location: 10 locations
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Status: Active
Location: 11 locations
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Status: Active
Location: 9 locations
Genetically Engineered Cells (19-28z/IL-18 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
Status: Active
Location: 7 locations
A Study of 131-I Apamistamab and CAR T-cell Therapy in Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
Status: Active
Location: 7 locations
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults with Blood Cancers Undergoing Donor Stem Cell Transplant
Status: Active
Location: 6 locations
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Status: Active
Location: 6 locations
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
Status: Active
Location: 6 locations
Total Therapy for Infants with Acute Lymphoblastic Leukemia, The TINI 2 Study
Status: Active
Location: 6 locations
BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
Status: Active
Location: 5 locations
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
Status: Active
Location: 5 locations